JUL 20 1770

TECH CENTER 1600/25

PATENT APPLICATION

Page 1 of 1

FORM PTO-1449		ATTY, DOCKET NO.	ADVEC9	SERIAL NO.	09/286,874	
OIPE		APPLICANT	Graham, et al.	<u> </u>		
10, 15		FILING DATE	04/06/99	GROUP	Unknown	1632
REFERENCE DESI	GNATION U	J.S. PATENT DOC	UMENTS			
AMINE RAP	DOCUMENT NUMBER	DATE	NAME		CLASS	SUB CLASS
LL_						l

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLAS	TRANS	LATION
PB	WO 95/27071		University of Texas (PCT)			YES	NO

OTHER REFERENCES (including Author, Title, Date, Pertinent Pages, etc.)

PB	Russ, Andreas P. et al., 1996. Self-Deleting Retrovirus Vectors for Gene Therapy. J. of Virology, pp. 4927-4932.
EXAMINER	Pete Pormod DATE CONSIDERED 10/20/00

PATENT APPLICATION

Page 1 of 5

FORM PTO-1449	ATTY. DOCKET NO.	ADVEC9	SERIAL NO.	09/286,874		
	APPLICANT	Graham, et al.				
	FILING DATE	04/06/99	GROUP	Unknewn-	1632	

REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS
PB	4,797,368	01/10/89	Carter, et al.) (S)	
PB	4,920,209	04/24/90	Davis, et al.	JUL 1 2 1990	
rB	4,920,211	04/24/90	Tibbetts, et al.	(6)	
PB	4,510,245	04/09/85	Cousens, et al.	EVE TRADEME	
PB	5,670,488	09/23/97	Gregory, et al.		
PB	5,882,877	03/16/99	Gregory, et al.		

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLAS	TRANS	LATION
FB	WO 93/19191	09/30/93	PCT			YES	NO
PB	WO 93/06223	04/01/93	PCT				X
PB	WO 94/08026	04/14/94	PCT			/	
PD	WO 97/32481	09/12/97	PCT			V	
PB	WO 94/12649	06/09/94	PCT			/	
PB	WO 93/19092	09/30/93	Defective Recombinant Adenoviruses Expressing Characteristic Epstein-Barr Virus Proteins				×
	WO96/13597	05/09/96	Improved Adenovirus and Methods of Use Thereof			/	

OTHER REFERENCES (including Author, Title, Date, Pertinent Pages, etc.)

PB		Anton, M., and F.L. Graham, 1995, Site-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: a molecular switch for control of gene expression, J. Virol. 69: 4600-4606.					
EXAMINER	Peter Brunoster	DATE CONSIDERED 10/20/60					

FORM PTO-1449	ATTY, DOCKET NO.	ADVEC9	SERIAL NO.	09/286,874
	APPLICANT	Graham, et al.		
	FILING DATE	04/06/99	GROUP	Unknown 1632

OTHER REFERENCES (including Author, Title, Date, Pertinent Pages, etc.)

Araki, K., J. Araki, J. I. Miyazski, and P. Vassali, 1995, Site-specific recombination of a transgene in
fertilized eggs by transient expression of Cre recombinase. Proc. Nat'l Acad. Sci. USA 92: 160-164.
Bett, A. J., L. Prevec, and F. L. Graham, 1993, Packaging capacity and stability of human adenovirus
type 5 vectors. J. Virol. 67: 5911-5921.
Bett, A. J., W. Haddara, L. Prev, and F.L. Graham, 1994, An efficient and flexible system for
construction of adenovirus vectors with insertions or deletions in early region 1 and 3. Proc. Nat'l
Acad. Sci. USA 91: 8802-8806.
Di Santo, J. P., W. Mueller, D. Guy-Grand, A. Fischer, and K. Rajewsky, 1995, Lymphoid
development in mice with a targeted deletion of the interleukin 2 receptor chain, Proc. Nat'l Sci. USA
92: 377-381.
Gage, P. J., B. Sauer, M. Levin and J. C. Glorioso. 1992. A cell-free recombination system for site-
specific integration of multigenic shittle plasmids into the herpes simplex virus type 1 genome. J.
Virol. 66: 5509-5515.
Graham, F. L. and L. Prevec. 1991. Manipulation of adenovirus vectors. In Murray E. J. (ed.),
Methods in Molecular Biology. The Human Press Inc. Clifton, N. J. Vol. 7 (Gene Transfer Protocols):
109-128
Graham, F. L. and L. Prevec. 1992. Adenovirus-based expression vectors and recombinant vaccines.
in: Vaccines: New Approaches in Immunological Problems., ed. Ellis, R. W. Butterworth-Heinemann
Boston, MA: 363-390.
Graham, F. L., J. Smiley, W.C. Russel and R. Naim. 1977. Characteristics of a human cell line
transformed by DNA from human adenovirus type 5., J. Gen. Virol. 36: 59-72.
Gu, H., J.D. Marth, P.C. Orban, H. Mossmann and K. Rajewsky. 1994. Deletion of a DNA
polymerase B gene segement in T cells using cell type-specific gene targeting. Science 265: 103-106.
Kilby, N.J., M. R. Snaith, and J. A. H. Murray. 1993. Site-specific recombinases: tools for genome
engineering. Trends Genet. 9: 413-421.
A DATE CONSIDERED
Pete Romande 10/20/00

RECEIVED

JUL 20 1998

TECH CENTER 1600/2900

PATENT APPLICATION Page 3 of 5

FORM PTO-1449		ATTY. DOCKET NO.	ADVEC9	SERIAL NO.	09/286,874	1
		APPLICANT	Graham, et al.			
		FILING DATE	04/06/99	GROUP	Unknown	1632
	ОТНЕ	R REFERENCES (including Author, T	itle, Date, Pert	inent Pages,	etc.)
· PB	mammalian cells 6991-6995.	using a ligand-depe	i P. Chambon. 1995 Indent chimeric Cre p 1993. Timing of S	rotein. Proc. Na	at'l Acad. Sci	. USA 92:
	Oncogene 8: 3333	3-3342.	tumor progression of			
	521-527.	·	•			
	Sauer, B., and N. Henderson. 1990. Targeted insertion of exogenous DNA into the eukaryotic geno by the Cre recombinase. The New Biologist 2: 441-449. Sauer B., M Whealy, A. Robbins and L. Enquist. 1987. Site-specific insertion of DNA into					
	pseudorabies virus vector. Proc. Nat'l. Acad. Sci. USA 84: 9108-9112.					
	Smith, A. J. H., M. A. DeSousa, B. Kwabbi-Addo, A. Heppell-Parton, H. Impey, and P. Rabbits. 1 A site-directed chromosomal translocation induced in embryonic stem cells by Cre-loxP recombination. Nature Genetics 9: 376-385.					
		Evidence for multi	d K. Abremski. 1986 ple promotors and fo			
	Van Deursen, J., M. Fornerod, B. Van Rees, and G. Grosveld. 1995. Cre-mediated site specific translocation between non-homologous mouse chromosomes. Proc. Nat'l. Acad. Sci. USA 92: 7376-7380.					
PB	foreign gene expr		ison, D.C., Prevec, L			
EXAMINER Pe	te Br	l	DATE CONSIL	DERED Jo/20	100	

PATENT APPLICATION

Page 4 of 5

FORM PTO-144	ATTY, DOCKET NO. ADVEC9 SERIAL NO. 09/286,874						
	APPLICANT Graham, et al.						
	FILING DATE 04/06/99 GROUP Unknown 16:32						
	OTHER REFERENCES (including Author, Title, Date, Pertinent Pages, etc.)						
	Hanke, T., Frank L. Graham, Kenneth L. Rosenthal and David C. Johnson. 1991. Identification of an						
00	immunodominant cytotoxic t-lymphocyte recognition site in glycoprotein B of herpes simplex virus by						
PB	using recombinant adenovirus vectors and synthetic peptides. 1991. J. of Virology, 65: 1177-1186.						
	Graham, F. L., 1987. Growth of 293 cells in suspension culture. J. Gen. Virol. 68: 937-940.						
	Quantin, B., Leslie D. Pericaudet, Shahragim Tajbakhsh and Jean-Louis Mandel. 1992. Adenovirus as						
	an expression vector in muscle cells in vivo. Proc. Nat'l. Acad. Sci. 89: 2581-2584.						
	Rosenfeld, M. A. et al., 1992. In vivo transfer of the human cystic fibrosis transmembrane conductance						
	regulator gene to the airway epithelium, Cell. 68: 143-155.						
	W.J. McGrory, D.S. Baulista and F.L. Graham. 1988. A simple technique for the reuse of early region						
	1 mutations into infectious human adenovirus type 5, Virology 163: 614-617.						
	Wang, P., Anton, F. L. Graham and S. Bacchetti. High Frequency recombination between loxP sites in						
	human chromosomes mediated by an adenovirus vector expressing Cre recombinase. Submitted for						
	Publication.						
	Sauer, Brian and Nancy Henderson. 1988. Site-specific DNA recombination in mammalian cells by						
	the Cre recombinase of bacteriophage P1. Proc. Nat'l. Acad. Sci. USA 85: 5166-5170.						
	Gudrun Schiedner, et al., 1998. Genomic DNA transfer with a high-capacity adenovirus vector						
	results in improved in vivo gene expression and decreased toxicity. Nature Genetics 18: 180-183.						
	Manal A. Morsy, et al., 1998. An adenoviral vector deleted for all viral coding sequences results in						
	enhanced safety and extended expression of a leptin transgene. Proc. Nat'l. Acad. Sci. USA 95:						
	7866-7871.						

EXAMINER

Pate Romand

Jour. Virol. 71: 3 1842-1849.

DATE CONSIDERED

Stephen Hardy, et al., 1997. Construction of Adenovirus Vectors through Cre-lox Recombination.

10/20/00

PATENT APPLICATION

Page 5 of 5

FORM PTO-1449		ATTY. DOCKET NO.	ADVEC9	SERIAL NO.	09/286,874	
		APPLICANT	Graham, et al.			
		FILING DATE	04/06/99	GROUP	Unknown 1632	ZOIDE S
*	OTHER	REFERENCES (including Author, Titl	le, Date, Per	tinent Pages, etc.)	JUL 1 2 1999
2 -	Parks, et al., 1996	A helper-depende	nt adenovirus vector sy	stem: Remo	val of helper virus by Cre-	TRADEMINE
PB	mediated excision	of the viral package	ing signal. Proc. Nat'l.	Acad. Sci. U	ISA 93: 13565-13570.	G TRAUL!
	A. Kass-Eisler, L.	Leinwand, J. Gall,	B. Bloom and E. Falck	-Pedersen. 1	996. Cirumventing the	
	immune response to adenovirus-mediated gene therapy. Gene Therapy 3: 154-162.					
	Roy, S., Shirley, P	S., McClelland, A	and Kaleko, M. 1998	3. Circumver	ntion of Immunity to the	
	Adenovirus Major	Coat Protein Hexo	n. J. Virology 72: (8)	6875-6879.		
200	Mack, Charles A.	et al. 1997. Circur	nvention of Anti-Adend	ovirus Neutra	lizing Immunity by	
YB	Administration of	an Adenoviral Vect	or of an Alternate Sero	type. Hum.	Gene Therapy 8: 99-109.	
EXAMINER			DATE CONSIDE	RED		
Pe	te Bon	more		0/20/	00	
Rev. 10/94 (Form	3.05)					